MAP4K4在肺腺癌中的表达及与临床病理特征、放化疗疗效、预后的关系  

Expression of MAP4K4 in lung adenocarcinoma and its relationship with clinicopathologic features,radiochemotherapeutic efficacy and prognosis

作　　者：胡雯 孙文泽[2] 张丽 杨静 HU Wen;SUN Wenze;ZHANG Li;YANG Jing(Department of Oncology,Second Affiliated Hospital of Air Force Military Medical University,Xi′an,Shaanxi 710038,China;Department of Radiotherapy,First Affiliated Hospital,Xi′an Jiaotong University,Xi′an,Shaanxi 710061,China)

机构地区：[1]中国人民解放军空军军医大学第二附属医院肿瘤科,陕西西安710038 [2]西安交通大学第一附属医院放疗科,陕西西安710061

出　　处：《检验医学与临床》2024年第14期2112-2115,2130,共5页Laboratory Medicine and Clinic

基　　金：陕西省自然科学基础研究计划项目(2021JQ-403)。

摘　　要：目的 检测丝裂原激活蛋白激酶4(MAP4K4)在肺腺癌组织中的表达,探讨其与临床病理特征、放化疗疗效及预后的关系。方法 选择2018年5月至2020年7月空军军医大学第二附属医院收治的121例经肺穿刺组织活检或支气管镜活检确诊的非手术肺腺癌患者癌组织标本;另选取同期接受手术治疗获得的20例肺腺癌患者癌旁正常组织标本作为对照。采用免疫组化法检测不同组织中MAP4K4表达水平,并分析MAP4K4表达与肺腺癌临床病理特征、放化疗疗效及预后的关系。结果 肺腺癌组织中MAP4K4阳性表达率高于癌旁正常组织(45.5%vs. 0.0%,P<0.05)。MAP4K4表达与分化程度、淋巴结转移、远处转移及TNM分期有关(P<0.05)。MAP4K4阳性患者客观有效率明显低于阴性患者,差异有统计学意义(P<0.05);MAP4K4表达与放化疗疗效呈负相关(r=-0.309,P<0.05)。MAP4K4阳性者中位无进展生存期及总生存期短于阴性者,差异有统计学意义(P<0.05)。结论 肺腺癌组织中MAP4K4高表达,且与临床病理特征及放化疗疗效密切相关,阳性表达患者预后较差。MAP4K4有望作为评估肺腺癌放化疗疗效及预后的有效分子标志物。Objective To detect the expression of mitogen-activated protein kinase 4(MAP4K4)in lung adenocarcinoma tissue,and to explore its relationship with clinicopathological features,radiochemotherapeutic effect and prognosis.Methods The samples from 121 patients with non-operative lung adenocarcinoma tissues confirmed by lung puncture biopsy or bronchoscopic biopsy in the Second Affiliated Hospital of Air Force Military Medical University from May 2018 to July 2020 were retrospectively collected;in addition,20 paracancerous normal tissue samples from the patients with lung adenocarcinoma receiving the operation treatment during the same period were selected as the controls.The immunohistochemical method was used to detect the MAP4K4 protein expression level in different tissues,and the relationship between the MAP4K4 expression with clinicopathological features,radiochemotherapeutic efficacy and prognosis of lung adenocarcinoma was analyzed.Results The positive expression rate of MAP4K4 in lung adenocarcinoma tissues was higher than that in paracancerous normal tissues(45.5%vs.0.0%,P<0.05).The MAP4K4 expression was related to the differentiation degree,lymph node metastasis,distant metastasis and TNM stage(P<0.05).The objective response rate in the patients with MAP4K4 positive was significantly lower than that in the patients with MAP4K4 negative,and the difference was statistically significant(P<0.05).The MAP4K4 expression was negatively correlated with the efficacy of chemoradiotherapy(r=-0.309,P<0.05).The median progression free survival and overall survival in the patients with MAP4K4 positive were shorter than those in the patients with MAP4K4 negative,and the difference was statistically significant(P<0.05).Conclusion The expression of MAP4K4 in lung adenocarcinoma tissues is high,and it is closely related to clinicopathological features and radiochemotherapeutic efficacy,moreover the prognosis in the patients with MAP4K4 positive expression is poor.MAP4K4 is expected to serve as an effective molecular marker fo

关 键 词：肺腺癌 丝裂原激活蛋白激酶4 病理特征 放化疗 预后 

分 类 号：R734.2[医药卫生—肿瘤] R446.8[医药卫生—临床医学]